PFDN及其亚基在肿瘤发生发展中的作用

doi:10.3760/cma.j.cn371439-20240218-00060

国际肿瘤学杂志 ›› 2024, Vol. 51 ›› Issue (6): 350-353.doi: 10.3760/cma.j.cn371439-20240218-00060

PFDN及其亚基在肿瘤发生发展中的作用

郭泽浩, 张俊旺()

山西医科大学第二医院消化内科，太原 030000

收稿日期:2024-02-18 修回日期:2024-03-10 出版日期:2024-06-08 发布日期:2024-06-28
通讯作者: 张俊旺，Email： jasong@sxmu.edu.cn
基金资助:
山西省自然科学基金(201801D121327)

Role of PFDN and its subunits in tumorigenesis and tumor development

Guo Zehao, Zhang Junwang()

Department of Gastroenterology， Second Hospital of Shanxi Medical University， Taiyuan 030000， China

Received:2024-02-18 Revised:2024-03-10 Online:2024-06-08 Published:2024-06-28
Contact: Zhang Junwang， Email： jasong@sxmu.edu.cn
Supported by:
Natural Science Foundation of Shanxi Province of China(201801D121327)

摘要/Abstract

摘要：

前折叠蛋白（PFDN）作为共伴侣蛋白能够稳定新合成的肽，防止蛋白质错误折叠和聚集，在细胞骨架的形成中发挥重要作用。PFDN在神经胶质瘤、乳腺癌、肺癌、胃癌、肝癌、结直肠癌等多种肿瘤组织中表达上调，与肿瘤细胞的增殖和迁移密切相关。深入了解PFDN在肿瘤发生发展中的作用，可为PFDN在预防或逆转肿瘤进展方面提供新的思路和见解。

关键词: 肿瘤, 致癌作用, 前折叠蛋白

Abstract:

Prefoldin （PFDN） acts as a co-companion protein to stabilize newly synthesized peptides and prevent protein misfolding and aggregation. PFDN plays an important role in cytoskeleton formation. PFDN is upregulated in glioma， breast cancer， lung cancer， gastric cancer， liver cancer， colorectal cancer and other tumor tissues and is closely linked with the proliferation and migration of tumor cells. A deeper understanding of the role of PFDN in tumorigenesis and development may provide new ideas and insights for PFDN in preventing or reversing tumor progression.

Key words: Neoplasms, Carcinogenesis, Prefoldin

郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.

Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.

参考文献 27

[1]	Vainberg IE, Lewis SA, Rommelaere H, et al. Prefoldin, a chape-rone that delivers unfolded proteins to cytosolic chaperonin[J]. Cell, 1998, 93(5): 863-873. DOI: 10.1016/s0092-8674(00)81446-4. pmid: 9630229
[2]	Gestaut D, Roh SH, Ma BX, et al. The chaperonin TRiC/CCT associates with prefoldin through a conserved electrostatic interface essential for cellular proteostasis[J]. Cell, 2019, 177(3): 751-765.e15. DOI: 10.1016/j.cell.2019.03.012. pmid: 30955883
[3]	Tahmaz I, Shahmoradi Ghahe S, Topf U. Prefoldin function in cellular protein homeostasis and human diseases[J]. Front Cell Dev Biol, 2021, 9: 816214. DOI: 10.3389/fcell.2021.816214.
[4]	Wang P, Zhao J, Yang X, et al. PFDN1, an indicator for colorectal cancer prognosis, enhances tumor cell proliferation and motility through cytoskeletal reorganization[J]. Med Oncol, 2015, 32(12): 264. DOI: 10.1007/s12032-015-0710-z. pmid: 26553318
[5]	Miyazawa M, Tashiro E, Kitaura H, et al. Prefoldin subunits are protected from ubiquitin-proteasome system-mediated degradation by forming complex with other constituent subunits[J]. J Biol Chem, 2011, 286(22): 19191-19203. DOI: 10.1074/jbc.M110.216259. pmid: 21478150
[6]	Peñate X, Praena-Fernández JM, Romero Pareja P, et al. Over-expression of canonical prefoldin associates with the risk of mortality and metastasis in non-small cell lung cancer[J]. Cancers (Basel), 2020, 12(4): 1052. DOI: 10.3390/cancers12041052.
[7]	Zhao HC, Chen CZ, Yang CL, et al. Prefoldin and prefoldin-like complex subunits as predictive biomarkers for hepatocellular carcinoma immunotherapy[J]. Pathol Res Pract, 2022, 232: 153808. DOI: 10.1016/j.prp.2022.153808.
[8]	Jiang LL, Liu J. Prefoldin 6 promotes glioma progression via the AKT signalling pathway[J]. Cell Biol Int, 2023, 47(1): 52-62. DOI: 10.1002/cbin.11895.
[9]	Yang KY, Wu ZJ, Zhang H, et al. Glioma targeted therapy: insight into future of molecular approaches[J]. Mol Cancer, 2022, 21(1): 39. DOI: 10.1186/s12943-022-01513-z. pmid: 35135556
[10]	Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012—2016[J]. Neuro Oncol, 2019, 21(Suppl 5): v1-v100. DOI: 10.1093/neuonc/noz150.
[11]	Cai JY, Hu YY, Ye Z, et al. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour micro-environment in lower-grade glioma[J]. Front Immunol, 2022, 13: 1011757. DOI: 10.3389/fimmu.2022.1011757.
[12]	Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(6): 524-541. DOI: 10.3322/caac.21754.
[13]	Sarhangi N, Hajjari S, Heydari SF, et al. Breast cancer in the era of precision medicine[J]. Mol Biol Rep, 2022, 49(10): 10023-10037. DOI: 10.1007/s11033-022-07571-2. pmid: 35733061
[14]	Hashemi M, Arani HZ, Orouei S, et al. EMT mechanism in breast cancer metastasis and drug resistance: revisiting molecular interactions and biological functions[J]. Biomed Pharmacother, 2022, 155: 113774. DOI: 10.1016/j.biopha.2022.113774.
[15]	黄超有, 李玺, 韩铮, 等. Prefoldin 1对乳腺癌BT474细胞上皮-间充质转化的影响[J]. 实用医学杂志, 2019, 35(1): 47-50. DOI: 10.3969/j.issn.1006-5725.2019.01.010.
[16]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[17]	Li YT, Yan BS, He SM. Advances and challenges in the treatment of lung cancer[J]. Biomed Pharmacother, 2023, 169: 115891. DOI: 10.1016/j.biopha.2023.115891.
[18]	Wang D, Shi W, Tang Y, et al. Prefoldin 1 promotes EMT and lung cancer progression by suppressing cyclin A expression[J]. Oncogene, 2017, 36(7): 885-898. DOI: 10.1038/onc.2016.257. pmid: 27694898
[19]	Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives[J]. J Hematol Oncol, 2023, 16(1): 57. DOI: 10.1186/s13045-023-01451-3.
[20]	于晓鹏, 冯青青, 赵文飞, 等. 靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用[J]. 国际肿瘤学杂志, 2023, 50(10): 631-635. DOI: 10.3760/cma.j.cn371439-20230428-00120.
[21]	Zhou C, Guo ZY, Xu LQ, et al. PFND1 predicts poor prognosis of gastric cancer and promotes cell metastasis by activating the Wnt/β-catenin pathway[J]. Onco Targets Ther, 2020, 13: 3177-3186. DOI: 10.2147/OTT.S236929.
[22]	Malagoli Tagliazucchi G, Wiecek AJ, Withnell E, et al. Genomic and microenvironmental heterogeneity shaping epithelial-to-mesenchymal trajectories in cancer[J]. Nat Commun, 2023, 14(1): 789. DOI: 10.1038/s41467-023-36439-7. pmid: 36774358
[23]	Chen TN, He QM, Xiang ZX, et al. Identification and validation of key genes of differential correlations in gastric cancer[J]. Front Cell Dev Biol, 2021, 9: 801687. DOI: 10.3389/fcell.2021.801687.
[24]	He QM, Ding ZY, Chen TN, et al. PFDN2 promotes cell cycle progression via the hnRNPD-MYBL2 axis in gastric cancer[J]. Front Oncol, 2023, 13: 1164070. DOI: 10.3389/fonc.2023.1164070.
[25]	Shao YF, Yesseyeva G, Zhi YH, et al. Comprehensive multi-omics analysis and experimental verification reveal PFDN5 is a novel prognostic and therapeutic biomarker for gastric cancer[J]. Genomics, 2024, 116(2): 110821. DOI: 10.1016/j.ygeno.2024.110821.
[26]	Anwanwan D, Singh SK, Singh S, et al. Challenges in liver cancer and possible treatment approaches[J]. Biochim Biophys Acta Rev Cancer, 2020, 1873(1): 188314. DOI: 10.1016/j.bbcan.2019.188314.
[27]	Ke SJ, Lu SN, Wang CQ, et al. Comprehensive analysis of the prognostic value and functions of prefoldins in hepatocellular carcinoma[J]. Front Mol Biosci, 2022, 9: 957001. DOI: 10.3389/fmolb.2022.957001.

PFDN及其亚基在肿瘤发生发展中的作用

Role of PFDN and its subunits in tumorigenesis and tumor development

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 27

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[6]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[7]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[8]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[9]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[10]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[11]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[12]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[13]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[14]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[15]	傅旖, 马辰莺, 张露, 周菊英. 生境分析在恶性肿瘤影像组学中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 292-297.